Therapeutic antibody delivery: vector tools to boost efficacy and affordability
Abhishek Chiyyeadu1,2, Bushra Khan1, Katrin Ehrhardt1,2
1Institute of Experimental Hematology, Hannover Medical School, Hannover, Germany.
Frontiers in Immunology
|January 23, 2026
Summary
Gene therapy platforms like mRNA and viral vectors offer a promising alternative to traditional antibody production. These advanced methods can improve in vivo expression, reducing costs and enhancing patient access to antibody therapeutics.
Area of Science:
- Biotechnology and Gene Therapy
- Protein Engineering and Therapeutics
Background:
- Antibody (Ab)-based therapeutics are vital but face challenges in large-scale production and purification, limiting patient access.
- Advances in bioengineering have created next-generation antibody molecules with enhanced capabilities.
- Gene delivery platforms have matured, offering potential solutions for therapeutic protein production.
Purpose of the Study:
- To critically evaluate gene therapy platforms for improving in vivo expression of antibody therapeutics.
- To discuss strategies for enhancing in situ availability and efficacy of therapeutic proteins.
- To explore technological advancements, translational challenges, and future directions in gene therapy for antibody delivery.
Main Methods:
- Review of established and emerging gene therapy platforms (mRNA, viral vectors, engineered cell therapies).
- Analysis of clinical successes and regulatory landscape of gene delivery technologies.
- Evaluation of transient vs. stable expression systems for in situ protein availability.
Main Results:
- Gene therapy platforms demonstrate significant potential to transform antibody therapeutic delivery.
- In vivo expression via gene therapy can reduce manufacturing burdens, improve safety, and enhance tolerability.
- Successful clinical applications of mRNA vaccines, AAV, lentiviral vectors, and CAR-T cell therapies underscore platform maturity.
Conclusions:
- Harnessing gene therapy platforms can expand access to antibody therapeutics by improving in vivo expression.
- In situ expression offers benefits for engineered antibody-like molecules, potentially overcoming production and purification challenges.
- Optimizing gene therapy approaches is crucial for developing widely applicable clinical interventions for antibody therapeutics.
Keywords:
AAV vectorsantibody deliveryinfectious diseaseslentiviral vectorsmRNA-LNPplasma cell therapyMore Related Videos
Related Concept Videos
01:29Self-Efficacy
210
Self-efficacy is the belief in one's capacity to organize and execute actions necessary to manage prospective situations. This belief significantly influences how individuals approach goals, tasks, and challenges across different domains of life.Psychological and Educational ImpactsIndividuals with strong self-efficacy are more resilient in the face of difficulties. They are more likely to adopt effective problem-solving strategies, persist through obstacles, and regulate emotions such as...
210
01:13Therapeutic Index
6.7K
The therapeutic index of a drug is a key parameter in pharmacology that quantifies the relative safety of a drug by calculating the ratio between the dose that causes toxicity in half the population (50%) to the dose that proves to be effective for half the population (50%). It provides a spectrum of doses for a particular drug ranging from effective to potentially toxic. To illustrate, consider an anticoagulant agent like warfarin. It possesses a narrow window within its therapeutic index to...
6.7K
01:10Antibody Structure
65.4K
Overview
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
Antibodies, also known as immunoglobulins (Ig), are essential players of the adaptive immune system. These antigen-binding proteins are produced by B cells and make up 20 percent of the total blood plasma by weight. In mammals, antibodies fall into five different classes, which each elicits a different biological response upon antigen binding.
The Y-Shaped Structure of Antibodies Consists of Four Polypeptide Chains
Antibodies consist of four polypeptide chains: two identical heavy...
65.4K
01:22Scalar and Vectors
2.1K
In mechanics, commonly used terms like force, speed, velocity, and work can be classified as either scalar or vector quantities. A scalar is a physical quantity that can be described by its magnitude alone and does not require any directional components. Examples of scalar quantities are mass, area, and length.
Scalar quantities with the same physical units can be added or subtracted according to the usual algebra rules for numbers. For example, a class ending 10 min earlier than 50 min lasts...
Scalar quantities with the same physical units can be added or subtracted according to the usual algebra rules for numbers. For example, a class ending 10 min earlier than 50 min lasts...
2.1K
01:30Acceleration Vectors
21.8K
In everyday conversation, accelerating means speeding up. Acceleration is a vector in the same direction as the change in velocity, Δv, therefore the greater the acceleration, the greater the change in velocity over a given time. Since velocity is a vector, it can change in magnitude, direction, or both. Thus acceleration is a change in speed or direction, or both. For example, if a runner traveling at 10 km/h due east slows to a stop, reverses direction, and continues their run at 10 km/h...
21.8K
01:20Vector Operations
2.1K
Vectors are physical quantities that have both magnitude and direction. The vector operations include addition, subtraction, and scalar multiplication.
A vector multiplied by a scalar value is called scalar multiplication. The result obtained is a new vector with a different magnitude. If the scalar is positive, the direction of the vector remains the same, but if it is negative, the direction of the vector is reversed. For example, the product of the mass and velocity yields the momentum.
A vector multiplied by a scalar value is called scalar multiplication. The result obtained is a new vector with a different magnitude. If the scalar is positive, the direction of the vector remains the same, but if it is negative, the direction of the vector is reversed. For example, the product of the mass and velocity yields the momentum.
2.1K